Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results.
Nakamoto H, Yu XQ, Kim S, Origasa H, Zheng H, Chen J, Joo KW, Sritippayawan S, Chen Q, Chen HC, Tsubakihara Y, Tamai H, Song SH, Vaithilingam I, Lee KW, Shu KH, Hok-King Lo S, Isono M, Kurumatani H, Okada K, Kanoh H, Kiriyama T, Yamada S, Fujita T. Nakamoto H, et al. Among authors: vaithilingam i. Ther Apher Dial. 2020 Feb;24(1):42-55. doi: 10.1111/1744-9987.12840. Epub 2019 Jul 28. Ther Apher Dial. 2020. PMID: 31119846 Clinical Trial.
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. Baigent C, et al. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12. Lancet. 2011. PMID: 21663949 Free PMC article. Clinical Trial.
Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH; Oral Paricalcitol in ESRD Study Group. Ong LM, et al. Among authors: vaithilingam i. Nephrology (Carlton). 2013 Mar;18(3):194-200. doi: 10.1111/nep.12029. Nephrology (Carlton). 2013. PMID: 23311404 Clinical Trial.
Degradation of collagen type IV by C6 astrocytoma cells.
Del Maestro RF, Vaithilingam IS, McDonald W. Del Maestro RF, et al. Among authors: vaithilingam is. J Neurooncol. 1995;24(1):75-81. doi: 10.1007/BF01052662. J Neurooncol. 1995. PMID: 8523079
15 results